MONTREAL, March 13, 2019 /CNW/ - Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the appointment of Jamil Samsatly as Chief Scientific
Officer. Mr. Samsatly has been conducting research for the
past two years as a consultant on the Company's CELEXT07, a
bio-defense stimulant that has the potential of becoming a superior
eco-friendly alternative to synthetic fungicides, as part of a
collaboration project with McGill
University.
![Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/834751/Mondias_Natural_Products_Inc__Mondias_names_Jamil_Samsatly_as_Ch.jpg)
Mr. Samsatly is currently completing his Ph.D. at McGill University and has broad experience in
sustainable agriculture, healthy agri-food systems and molecular
biotechnology. He previously received an M.Sc. and B.Sc. in biology
and plant pathology from the American
University of Beirut. Working as a researcher for almost 10
years at well-recognized international institutions such as the
International Center for Agricultural Research in the Dry Areas
(ICARDA), Institut National de la Recherche Agronomique - Avignon,
the American University of Beirut and
McGill University has allowed him to
fully understand the challenges faced by agriculture globally, and
to develop a deep understanding of applied research and the types
of products that are needed in sustainable agriculture. Mr.
Samsatly is well recognized in his field of expertise, having
published in leading scientific journals and contributed to
building a broader picture of plant pathology and host-pathogen
interactions, with a special focus on the role of antioxidants and
vitamins.
"We are very pleased that Mr. Samsatly has agreed to play a
bigger role with Mondias as our Chief Scientific Officer," said
Jean-Philippe Gravel, Chief
Executive Officer of Mondias. "His dedicated research on our
CELEXT07 bio-defense stimulant has been promising in bringing this
product even closer to market. We strongly believe that his
knowledge and research expertise in the development of bio-controls
and bio-fertilizers for cannabis and other organic agriculture
production systems will greatly assist Mondias in fulfilling its
growth potential and achieve commercial success."
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the health care,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental
Sciences.
For more information, visit: mondias.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of this joint
venture, the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, the timing of clinical trials, the timing and outcomes of
regulatory or intellectual property decisions and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
SOURCE Mondias Natural Products Inc.